Ipilimumab Plus Dacarbazine Provide Survival Benefit in Advanced Melanoma

Share this content:
Ipilimumab plus dacarbazine provide a durable survival benefit at 5 years in patients treated for advanced melanoma.
Ipilimumab plus dacarbazine provide a durable survival benefit at 5 years in patients treated for advanced melanoma.

According to a study published online last week in the Journal of Clinical Oncology, ipilimumab plus dacarbazine provide a durable survival benefit at 5 years in patients treated for advanced melanoma.

Previous nonrandomized studies have shown that a proportion of ipilumumab-treated patients with advanced melanoma experience long-term survival, but researchers sought to investigate that benefit in a randomized, controlled phase III trial.

For the study, researchers enrolled 502 treatment-naive patients with advanced melanoma and randomly assigned them 1:1 to receive ipilimumab 10mg/kg plus dacarbazine or placebo plus dacarbazine at weeks 1, 4, 7, and 10 followed by dacarbazine alone every 3 weeks through week 22.

Eligible patients could then receive maintenance ipilimumab or placebo every 12 weeks beginning at week 24.

RELATED: At Year 3, Survival Curve of Ipilimumab-Treated Advanced Melanoma Begins to Plateau

Results showed that the 5-year survival rate for patients treated with ipilimumab plus dacarbazine was 18.2% (95% CI: 13.6 - 23.4) compared with 8.8% (95% CI: 5.7 - 12.8) for patients treated with placebo plus dacarbazine (P = 0.002).

Researchers observed a plateau in survival beginning at approximately 3 years. In regard to safety, among those who survived at least 5 years and continued to receive treatment with ipilimumab, grade 3 or 4 immune-related adverse events were only observed in the skin.

Reference

  1. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.56.6018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs